PDUFA Date Coming Up for U.K. Biopharma - The Streetwise Reports

Retrieved on: 2024-04-23 09:03:57

Tags for this article:

Food and Drug Administration

Pharmaceuticals policy

Canaccord Genuity

Genuity

Prescription Drug User Fee Act

Securities research

Financial Industry Regulatory Authority

Financial analyst

Investment banking

PDUFA date

Pharmaceutical industry in China

Chronic obstructive pulmonary disease

United Kingdom

Verona Pharma plc

u.s. food and drug administration

Click the tags to see associated articles and topics

PDUFA Date Coming Up for U.K. Biopharma - The Streetwise Reports. View article details on HISWAI: https://www.streetwisereports.com/article/2024/04/22/pdufa-date-coming-up-for-u-k-biopharma.html

Summary

Verona Pharma's ensifentrine, a treatment for COPD, awaits FDA approval with a PDUFA date set for June 26. Canaccord Genuity analyst projects a significant stock price increase upon approval. The article also discusses Verona's commercialization plans and future clinical trials. Key tags such as 'biopharma', 'chronic obstructive pulmonary disease', and 'pharmaceutical industry in China' are related to the article's focus on the pharmaceutical industry, drug approval processes, and market analysis.

Article found on: www.streetwisereports.com

View Original Article